Radioiodine
PreclinicalSmall molecule
Radioiodine is one of 9 small molecule programs targeting Differentiated Thyroid Carcinoma. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Differentiated Thyroid Carcinoma
#DrugCompanyPhaseTrials
1Cotellic
RochePhase 2
Anlotinib Hydrochloride
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Phase 2
Recombinant Human GM-CSF
EEastern Cooperative Oncology Group
Phase 2
AL2846
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Nexavar
BayerPreclinical
Radioactive Iodine Therapy
AstraZenecaPhase 2
Tirosint
IInstitut Jerome Lejeune
Preclinical
Radioiodine
ZZhujiang Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Radioiodine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- ZZhujiang Hospital